drugset / Trial / NCT00153036

Rt-PA in the Treatment of Acute Ischemic Stroke

NCT00153036

Phase 3 Completed 821 enrolled Boehringer Ingelheim
Treatment

Summary

To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.

Timeline

Start
2003-04
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications